Octreotide 20 mg [Mycapssa]
RxNorm 2380613
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2380613 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: octreotide 20 mg [Mycapssa].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDCPrescribable
Semantic Branded Drug Component (SBDC):
Octreotide 20 mg [Mycapssa]
(Atom ID: 12412082)
Patient Education
Octreotide
Octreotide is used to treat acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) in people who have been treated successfully with octreotide injection (Sandostatin) or lanreotide injection (Somatuline). Octreotide is in a class of medications called octapeptides. It works by decreasing the amounts of certain natural substances produced by the body.
[Learn More]
* Please review the disclaimer below.